Revenue YoY
+82.57%
Operating Income YoY
+751.92%
Net Income YoY
+314.00%
Net Margin Δ
+2499 bps
Net income bridge for Alnylam Pharmaceuticals (ALNY) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Net income: $847M+314.00%
Profit bridge breakdown for Alnylam Pharmaceuticals (ALNY) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Net Income | -$270M | — |
| Revenue | $1.94B | +228.9% |
| Cost of Revenue | -$491M | -57.9% |
| Operating Expenses | -$581M | -68.6% |
| Other Income / Expense | $74.3M | +8.8% |
| Income Tax | -$63.5M | -7.5% |
| Other Items | -$31.3M | -3.7% |
| Net Income | $577M | — |
- Prior Net Income-$270M
- Revenue$1.94B
- Cost of Revenue-$491M
- Operating Expenses-$581M
- Other Income / Expense$74.3M
- Income Tax-$63.5M
- Other Items-$31.3M
- Net Income$577M
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want the full P&L structure?Income Statement Waterfall
Frequently asked questions
Data & methodology
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Forecast & Valuation
Operations
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement
Capital Return
How this company returns cash to shareholders — buybacks, dividends, and stock splits.